IL-18 might reflect disease activity in mild and moderate asthma exacerbation
IL-18 might reflect disease activity in mild and moderate asthma exacerbation
复制标题
DOI：
10.1067/mai.2001.112275
复制
发表时间：
2001-02-01
影响因子：
14.2
通讯作者：
Abe, S
中科院分区：
文献类型：
--
作者：
Tanaka, H;Miyazaki, N;Abe, S
背景：IL-18是一种IFN-γ诱导因子，是一种促炎细胞因子，在T（H）1细胞活化中起重要作用。近年来研究表明，组胺可诱导IL-18的产生，IL-18可能是T（H）1和T（H）2细胞因子的共诱导剂。血清IL-18、可溶性IL-2受体、嗜酸性粒细胞阳离子蛋白和血浆IFN-γ水平，对稳定期哮喘（n = 28）、急性轻度或中度哮喘（n = 23）、肺结节病（n = 35）和健康受试者（n = 26）进行了呼气峰流速测定。比较哮喘急性发作期与缓解期患者血清IL-18水平，并观察哮喘治疗后急性发作期患者血清IL-18水平的变化（215 +/- 33 pg/mL，平均值+/- SE; P = .02）和肺结节病（239 +/- 27 pg/mL，P = .008）（127 +/- 11 pg/mL），但血浆IFN-γ水平仅在肺结节病中显著升高（P < .001）。在肺结节病中，IL-18值与IFN-γ水平显著相关（r = 0.61，P <0.001），但在急性哮喘中，两者不相关。哮喘急性发作期的IL-18水平显著高于缓解期（P = 0.01）。在急性哮喘中，循环IL-18水平与血清可溶性IL-2受体水平显著相关（r = 0.77，P <0.0001），但与血清嗜酸性粒细胞阳离子蛋白水平无关。IL-18水平与最大呼气流量呈负相关。IL-18水平在治疗后第3天迅速下降（P = 0.02），治疗后第3天下降（P = 0.002）。结论：IL-18在轻、中度哮喘急性发作时可能起着激活免疫应答的作用，可反映病情活动。
Background: IL-18, identified as an IFN-gamma -inducing factor, is a proinflammatory cytokine that plays an important role in T(H)1 cell activation. Recently, it was reported that histamine induced IL-18 and that IL-18 might act as a coinducer of T(H)1 and T(H)2 cytokines.Objective: The aim was to evaluate the contribution of IL-18 to asthma exacerbation.Methods: Serum IL-18, soluble IL-2 receptor, eosinophil cationic protein, and plasma IFN-gamma levels, as well as peak expiratory flow were measured in patients with stable asthma (n = 28), acute mild or moderate asthma (n = 23), or pulmonary sarcoidosis (n = 35) and in healthy subjects (n = 26). We compared the serum IL-18 levels between patients with acute asthma and those in remission and examined the time course in acute exacerbation after asthma therapy.Results: Significantly higher serum IL-18 levels were found in patients with acute asthma (215 +/- 33 pg/mL, mean +/- SE; P = .02) and pulmonary sarcoidosis (239 +/- 27 pg/mL, P = .008) than in control subjects (127 +/- 11 pg/mL), but the plasma IFN-gamma level was significantly elevated in only pulmonary sarcoidosis (P < .001). In pulmonary sarcoidosis the IL-18 values significantly correlated with the IFN- levels (r = 0.61, P < .001), but in acute asthma they did not. The IL-18 levels during acute asthma exacerbation were significantly higher (P = .01) than on remission days. In acute asthma, circulating IL-18 levels significantly correlated with serum soluble IL-2 receptor levels (r = 0.77, P < .0001) but not with serum eosinophil cationic protein levels. The IL-18 level had a tendency to inversely correlate with peak expiratory flow. The elevated IL-18 levels in acute asthma quickly decreased on day 3 (P = .02) and day 3 (P = .002) after therapy.Conclusion: It was suggested that IL-18 may play a potential role to activate immunologic responses and may reflect disease activity in mild and moderate asthma exacerbation.